Blog
TB-500: chemical identity must come before healing claims
The paper addresses a basic question: what molecule is being discussed? Transferring results requires a matching sequence and formulation. A shared trade label cannot establish that match.
Evidence discussed: Analytical identity study.
What the researchers studied
An analytical study identified an acetylated fragment corresponding to residues 17–23 of thymosin beta-4 in a preparation described as TB-500. Chromatography and high-resolution mass spectrometry characterized the material. [1]
How to interpret the result
The finding does not prove what every TB-500-labelled product contains. It establishes neither human healing benefits nor interchangeability with full-length thymosin beta-4 used in other studies.
What readers can take from it
The paper addresses a basic question: what molecule is being discussed? Transferring results requires a matching sequence and formulation. A shared trade label cannot establish that match.
This original editorial summary provides no diagnosis, dosing or treatment advice. The study did not test or certify a PeptiKing product.
Source
[1] Esposito et al., identification of a TB-500 fragment (2012). PMID: 22962027. Based on the PubMed-indexed abstract and record; full-text methods were not independently reviewed.